Accessibility Menu
Stoke Therapeutics logo

Stoke Therapeutics(NASDAQ) STOK

Market Cap$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+17%
5 Year+18%
1 Year+52%
1 Month-7%
Premium Feature
Moneyball Superscore
75/100
$29.76
-0.77%
-0.23Today
After hours$29.81+$0.04 (+0.15%)
Stoke Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 29.812026-09-04
Stoke Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.72%USD 31.622026-08-28
1 month-6.64%USD 31.932026-08-05
3 month-0.67%USD 30.012026-06-05
Year to date-6.08%USD 31.742025-12-31
1 year+51.86%USD 19.632025-09-04
3 year+444.97%USD 5.472023-09-05
5 year+17.59%USD 25.352021-09-03
Since inception+16.58%USD 25.572019-06-19

Stoke Therapeutics Financials at a Glance

Market Cap

$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$27.59M

Net Income (TTM)

-$207.90M

EPS (TTM)

-$3.37

P/E Ratio

-8.84

Dividend

$0.00

Beta (Volatility)

1.39 (Average)

Price

$29.76

Volume

714,062.077

Open

$29.41

Previous Close

$29.81

Daily Range

$29.15 - $30.03

52-Week Range

$20.32 - $40.22

Estimated Earnings Date

Nov 3, 2026

STOK News

SellAlert-Purple.png

Stoke Therapeutics Stock Up 340% as Chair Sells $174K in Shares

Jonathan PoncianoMar 27, 2026
SellAlert-Purple.png

Stoke Therapeutics CMO Sells $457,000 in Stock Amid 300% Rally

Jonathan PoncianoMar 24, 2026
SellAlert-Green.png

Stoke Therapeutics' Chief Medical Officer Sold Over 5,000 Shares in the Company. Should Shareholders Sell?

Robert IzquierdoDec 10, 2025
growth curve

This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street

George Budwell, PhDAug 16, 2023
scientist looking through microscope (2)

Why Shares of Stoke Therapeutics Plummeted Tuesday

James HalleyJul 25, 2023
Getty Chemists in Lab Multicultural

Why Shares of Stoke Therapeutics Plummeted in September

John BromelsOct 8, 2019
stock chart

Are There Good Investments Among 2019's Biotech IPOs?

David HaenOct 2, 2019

STOK: Motley Fool Moneyball Superscore

75

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Stoke Therapeutics

Stoke Therapeutics, Inc. makes medicines for people with rare genetic diseases. These treatments help the body create proteins it currently lacks. This process aims to stop or slow down severe health conditions.

What Is in the Pipeline?

  • Zorevunersen: Clinical candidate for Dravet syndrome, a severe form of epilepsy starting in infancy; currently in Phase 3 testing.
  • STK-002: Experimental treatment for an inherited condition that causes vision loss; currently in Phase 1 trials.
  • TANGO Platform: Proprietary technology designed to increase protein levels by targeting the body's RNA (ribonucleic acid).
  • SCN1A Compounds: Genetic targets for epilepsy being developed in partnership with Biogen.

Steps Toward Commercialization

  • Entered a collaboration with Biogen in Feb. 2025 to develop and commercialize treatments for SCN1A-related diseases.
  • Launched the global Phase 3 EMPEROR study for zorevunersen in May 2025.
  • Appointed Thomas McCauley as Chief Scientific Officer in July 2026 to lead scientific strategy.
  • Expanded headquarters and laboratory space in Waltham, Massachusetts, through a new lease agreement in Jan. 2026.

Why the TANGO Platform Matters

Stoke uses its TANGO platform to address diseases caused by haploinsufficiency. This occurs when one gene copy fails to produce enough protein for the body to function normally.

Vital Statistics and Financial Results

  • Revenue was $15.6 million for the six months ended June 30, 2026, compared to $172.4 million in the prior-year period.
  • Net loss reached $111.6 million for the six-month period ended June 30, 2026.
  • Cash, cash equivalents, and marketable securities totaled $354.3 million as of June 30, 2026.
  • Research and development expenses increased to $89.2 million for the first half of 2026.
  • Sold common stock for net proceeds of $65.7 million between June 30, 2026, and Aug. 2026.

How Stoke Has Evolved

Stoke has transitioned from a research-focused startup to a late-stage clinical company. Its collaborations with global partners support the development of medicines for rare genetic conditions.

AI Generated • Aug 4, 2026

Industry

Biotechnology

Sector

Health Care

Employees

170

CEO

Ian Frederick Smith, CPA

Website

www.stoketherapeutics.com

Headquarters

Bedford, MA 01730, US

STOK Financials

Key Financial Metrics (TTM)

Gross Margin

84.67%

Operating Margin

-809.69%

Net Income Margin

-753.60%

Return on Equity

-59.36%

Return on Capital

-5.79%

Return on Assets

-52.77%

Earnings Yield

-11.31%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

64.53M

Volume

714.06K

Avg. Volume

871.22K

Financials (TTM)

Gross Profit

$23.36M

Operating Income

-$223.38M

EBITDA

-$205.36M

Operating Cash Flow

-$177.99M

Capital Expenditure

-$2.69M

Free Cash Flow

-$180.68M

Cash & ST Invst.

$292.82M

Total Debt

$2.68M

Stoke Therapeutics Performance Analysis

Stoke Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 12,405,000N/A
20232023-12-31USD 8,780,000-29.2%
20242024-12-31USD 36,555,000316.3%
20252025-12-31USD 184,420,000404.5%
Stoke Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-23.1%
Q42025-12-31-86.8%
Q12026-03-31344.3%
Q22026-06-3049.7%
Stoke Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.6011.3%
20232023-12-31USD -2.38-8.4%
20242024-12-31USD -1.65-30.8%
20252025-12-31USD -0.12-92.9%
Stoke Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-62.5%
Q42025-12-31-52.3%
Q12026-03-3120.2%
Q22026-06-30-17.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$9.33M

-32.5%

Gross Profit

$8.19M

-40.7%

Gross Margin

87.80%

N/A

Market Cap

$1.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.31M

N/A

Employees

170

N/A

Net Income

-$61.62M

-162.4%

EBITDA

-$64.29M

-179.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$292.82M

+18.2%

Total Debt

$2.68M

+16.8%

Accounts Receivable

$8.72M

+437.5%

Inventory

$0.00

N/A

Long Term Debt

$837.00K

N/A

Short Term Debt

$1.85M

-19.6%

Return on Assets

-52.77%

N/A

Return on Invested Capital

-63.45%

N/A

Free Cash Flow

-$58.56M

-129.0%

Operating Cash Flow

-$56.59M

-122.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NTLAIntellia Therapeutics, Inc.
$12.74+0.47%
ZBIOZenas BioPharma, Inc.
$32.88-0.12%
ZYMEZymeworks Inc.
$29.19-2.37%
NVAXNovavax, Inc.
$10.22-1.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About STOK

What is the current price of Stoke Therapeutics?

Stoke Therapeutics is trading at $29.81 per share.

What is the 52-week range for Stoke Therapeutics?

Over the past 52 weeks, Stoke Therapeutics has traded between $20.32 and $40.22.

How much debt does Stoke Therapeutics have?

As of the most recent reporting period, Stoke Therapeutics reported total debt of $2.68M.

How much cash does Stoke Therapeutics have on hand?

Stoke Therapeutics reported $110.00M in cash and cash equivalents in its most recent financial results.

What is Stoke Therapeutics’s dividend yield?

Stoke Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services